541 related articles for article (PubMed ID: 30654298)
21. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Procaccio L; Merz V; Fasano M; Vaccaro V; Giommoni E; Pretta A; Noventa S; Satolli MA; Giordano G; Zichi C; Pinto C; Zecchetto C; Barsotti G; De Vita F; Milella M; Antonuzzo L; Scartozzi M; Zaniboni A; Spadi R; Casalino S; Bergamo F; De Toni C; Melisi D; Lonardi S
Cancer Med; 2023 Jul; 12(13):14337-14345. PubMed ID: 37278395
[TBL] [Abstract][Full Text] [Related]
22. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Chiu TJ; Yang SH; Chiu SC; Hsueh SW; Chiang NJ; Li CP; Bai LY; Cheng FM; Chuang SC; Shan YS; Chan DC; Chen LT; Yen CJ; Peng CM; Su YY; Chen YY; Chen JS; Chou WC
J Hepatobiliary Pancreat Sci; 2022 Jun; 29(6):670-681. PubMed ID: 35182031
[TBL] [Abstract][Full Text] [Related]
23. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer.
Chen LT; Macarulla T; Blanc JF; Mirakhur B; Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357748
[TBL] [Abstract][Full Text] [Related]
24. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
[TBL] [Abstract][Full Text] [Related]
25. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Taghizadeh H; Unseld M; Schmiderer A; Djanani A; Wilthoner K; Buchinger D; Prager GW
Cancer Chemother Pharmacol; 2020 Jul; 86(1):109-115. PubMed ID: 32556829
[TBL] [Abstract][Full Text] [Related]
26. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Barzi A; Miksad R; Surinach A; Corvino FA; Wang S; Torres AZ; Mamlouk K; Pulgar S; Valderrama A; Bekaii-Saab T; Ahn D
Pancreas; 2020 Feb; 49(2):193-200. PubMed ID: 32011529
[TBL] [Abstract][Full Text] [Related]
27. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy.
Bang K; Cheon J; Jeong JH; Im HS; Kim KP; Ryoo BY; Yoo C
Ther Adv Med Oncol; 2021; 13():17588359211003053. PubMed ID: 33796153
[TBL] [Abstract][Full Text] [Related]
29. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
31. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
Merz V; Messina C; Zecchetto C; Quinzii A; Frisinghelli M; Trentin C; Salati M; Caffo O; Melisi D
Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):87-97. PubMed ID: 38129199
[TBL] [Abstract][Full Text] [Related]
32. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
[TBL] [Abstract][Full Text] [Related]
33. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Ko AH
Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
[TBL] [Abstract][Full Text] [Related]
34. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Takada R; Ikezawa K; Yamai T; Watsuji K; Seiki Y; Kawamoto Y; Hirao T; Higashi S; Urabe M; Kai Y; Nakabori T; Uehara H; Kotani M; Yagi T; Kimura M; Nozaki K; Takagi M; Ohkawa K
BMC Cancer; 2023 Jul; 23(1):711. PubMed ID: 37518012
[TBL] [Abstract][Full Text] [Related]
35. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma.
Chun JW; Woo SM; Lee SH; Choi JH; Park N; Kim JS; Cho IR; Paik WH; Lee WJ; Ryu JK; Kim YT
Ther Adv Med Oncol; 2022; 14():17588359221119539. PubMed ID: 36062047
[TBL] [Abstract][Full Text] [Related]
36. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
37. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
38. [Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
Ueno M
Gan To Kagaku Ryoho; 2020 Jun; 47(6):955-962. PubMed ID: 32541174
[TBL] [Abstract][Full Text] [Related]
39. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.
Yoo C; Im HS; Kim KP; Oh DY; Lee KH; Chon HJ; Kim JH; Kang M; Kim I; Lee GJ; Oh SY; Choi Y; Choi HJ; Kim ST; Park JO; Ryoo BY
Ther Adv Med Oncol; 2019; 11():1758835919871126. PubMed ID: 31489036
[TBL] [Abstract][Full Text] [Related]
40. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Bockorny B; Macarulla T; Semenisty V; Borazanci E; Feliu J; Ponz-Sarvise M; Abad DG; Oberstein P; Alistar A; Muñoz A; Geva R; Guillén-Ponce C; Fernandez MS; Peled A; Chaney M; Gliko-Kabir I; Shemesh-Darvish L; Ickowicz D; Sorani E; Kadosh S; Vainstein-Haras A; Hidalgo M
Clin Cancer Res; 2021 Sep; 27(18):5020-5027. PubMed ID: 34253578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
